CureVac (NASDAQ:CVAC) Shares Gap Up – What’s Next?

CureVac (NASDAQ:CVAC)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $2.79, but opened at $2.95. CureVac shares last traded at $2.88, with a volume of 171,953 shares changing hands.

Analyst Ratings Changes

Separately, JMP Securities reissued a “market outperform” rating and issued a $16.00 price target on shares of CureVac in a research note on Monday, September 16th.

CureVac Stock Down 4.5 %

The stock has a market cap of $615.67 million, a price-to-earnings ratio of 5.15, a PEG ratio of 2.04 and a beta of 2.61. The company has a quick ratio of 2.28, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The stock has a fifty day moving average of $2.93 and a two-hundred day moving average of $3.26.

CureVac (NASDAQ:CVAC) last posted its earnings results on Thursday, August 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). CureVac had a return on equity of 25.55% and a net margin of 20.72%. The business had revenue of $15.55 million for the quarter, compared to analyst estimates of $10.07 million. As a group, analysts predict that CureVac will post 0.05 EPS for the current fiscal year.

Hedge Funds Weigh In On CureVac

Institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC acquired a new stake in CureVac during the 3rd quarter valued at approximately $30,000. International Assets Investment Management LLC acquired a new stake in shares of CureVac during the third quarter worth approximately $35,000. Bank of New York Mellon Corp bought a new stake in shares of CureVac in the second quarter worth $54,000. Ballentine Partners LLC raised its holdings in CureVac by 58.6% in the third quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock valued at $67,000 after acquiring an additional 8,406 shares in the last quarter. Finally, Signaturefd LLC boosted its stake in CureVac by 232.0% during the 2nd quarter. Signaturefd LLC now owns 22,043 shares of the company’s stock valued at $75,000 after acquiring an additional 15,403 shares during the last quarter. Institutional investors and hedge funds own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.